PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTCT POWR Grades
- PTCT scores best on the Value dimension, with a Value rank ahead of 79.75% of US stocks.
- PTCT's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- PTCT ranks lowest in Sentiment; there it ranks in the 4th percentile.
PTCT Stock Summary
- Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 15.27% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 70.7%, Ptc Therapeutics Inc's debt growth rate surpasses 88.65% of about US stocks.
- As for revenue growth, note that PTCT's revenue has grown 33.82% over the past 12 months; that beats the revenue growth of 84.25% of US companies in our set.
- Stocks that are quantitatively similar to PTCT, based on their financial statements, market capitalization, and price volatility, are INFN, FBIO, CHRS, MDWD, and CREX.
- PTCT's SEC filings can be seen here. And to visit Ptc Therapeutics Inc's official web site, go to www.ptcbio.com.
PTCT Valuation Summary
- PTCT's price/sales ratio is 6.7; this is 86.11% higher than that of the median Healthcare stock.
- PTCT's price/earnings ratio has moved down 9.1 over the prior 98 months.
- PTCT's price/earnings ratio has moved down 9.1 over the prior 98 months.
Below are key valuation metrics over time for PTCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTCT | 2020-01-30 | 10.6 | 4.8 | -14.2 | -13.9 |
| PTCT | 2018-06-29 | 7.0 | 10.4 | -22.6 | -29.6 |
| PTCT | 2018-05-23 | 6.1 | 9.2 | -19.9 | -26.1 |
| PTCT | 2018-03-20 | 6.9 | 8.6 | -17.1 | -21.1 |
| PTCT | 2014-10-31 | 38.9 | 5.5 | -20.0 | -19.4 |
| PTCT | 2014-03-24 | 23.0 | 5.8 | -12.0 | -18.6 |
PTCT Growth Metrics
- Its 2 year price growth rate is now at 65.65%.
- The 3 year net cashflow from operations growth rate now stands at 58.17%.
- Its year over year net cashflow from operations growth rate is now at -54.35%.
The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 430.449 | -212.674 | -454.115 |
| 2020-12-31 | 380.766 | -194.071 | -438.16 |
| 2020-09-30 | 358.361 | -139.911 | -441.483 |
| 2020-06-30 | 311.373 | -182.072 | -431.788 |
| 2020-03-31 | 321.656 | -137.784 | -292.15 |
| 2019-12-31 | 306.98 | -98.639 | -251.576 |
PTCT Price Target
For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $61.58 | Average Broker Recommendation | 1.62 (Moderate Buy) |
PTCT Stock Price Chart Interactive Chart >
PTCT Price/Volume Stats
| Current price | $38.99 | 52-week high | $70.82 |
| Prev. close | $38.33 | 52-week low | $37.12 |
| Day low | $38.15 | Volume | 63,492 |
| Day high | $39.50 | Avg. volume | 524,167 |
| 50-day MA | $41.89 | Dividend yield | N/A |
| 200-day MA | $52.50 | Market Cap | 2.75B |
PTC Therapeutics, Inc. (PTCT) Company Bio
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.
Latest PTCT News From Around the Web
Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
PTC Therapeutics EPS beats by $0.13, beats on revenuePTC Therapeutics (NASDAQ:PTCT): Q2 GAAP EPS of -$1.68 beats by $0.13. Revenue of $116.7M (+55.1% Y/Y) beats by $6.42M. Press Release... |
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial ResultsPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021. |
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England Journal of Medicine. This trial showed that symptomatic Type 1 spinal muscular atrophy (SMA) infants treated with Evrysdi™ (risdiplam) showed significant improvements in survival, motor milestones, and motor function compared to historical controls. |
PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleasePTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] |
PTCT Price Returns
| 1-mo | -9.51% |
| 3-mo | 1.35% |
| 6-mo | -35.84% |
| 1-year | -15.84% |
| 3-year | 3.81% |
| 5-year | 522.84% |
| YTD | -36.11% |
| 2020 | 27.07% |
| 2019 | 39.95% |
| 2018 | 105.76% |
| 2017 | 52.89% |
| 2016 | -66.33% |
Continue Researching PTCT
Want to do more research on Ptc Therapeutics Inc's stock and its price? Try the links below:Ptc Therapeutics Inc (PTCT) Stock Price | Nasdaq
Ptc Therapeutics Inc (PTCT) Stock Quote, History and News - Yahoo Finance
Ptc Therapeutics Inc (PTCT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...